A prospective, randomized, multi-center, open-label, comparative safety and efficacy study of prophylactically administered pegylated interferon alfa-2a (Pegasys) [peginterferon alfa-2a] plus ribavirin vs. no prophylaxis following liver transplantation for hepatitis C
Phase of Trial: Phase IV
Latest Information Update: 09 Nov 2011
At a glance
- Drugs Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 20 May 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 26 Jan 2010 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 26 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.